These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 24310604)

  • 1. Treatment of Parkinson's disease: what's in the non-dopaminergic pipeline?
    Hung AY; Schwarzschild MA
    Neurotherapeutics; 2014 Jan; 11(1):34-46. PubMed ID: 24310604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-dopaminergic treatments for motor control in Parkinson's disease.
    Fox SH
    Drugs; 2013 Sep; 73(13):1405-15. PubMed ID: 23917951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is there room for new non-dopaminergic treatments in Parkinson's disease?
    Pilleri M; Koutsikos K; Antonini A
    J Neural Transm (Vienna); 2013 Feb; 120(2):349-52. PubMed ID: 23229903
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapy of the motor symptoms in the advanced stage of Parkinson's disease.
    Takahashi K
    Nihon Rinsho; 2017 Jan; 75(1):77-82. PubMed ID: 30566298
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current and investigational non-dopaminergic agents for management of motor symptoms (including motor complications) in Parkinson's disease.
    Müller T
    Expert Opin Pharmacother; 2017 Oct; 18(14):1457-1465. PubMed ID: 28847181
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neural substrates and potential treatments for levodopa-induced dyskinesias in Parkinson's disease.
    Phillips JR; Eissa AM; Hewedi DH; Jahanshahi M; El-Gamal M; Keri S; Moustafa AA
    Rev Neurosci; 2016 Oct; 27(7):729-738. PubMed ID: 27362959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Chase TN
    Drugs; 1998; 55 Suppl 1():1-9. PubMed ID: 9483164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safinamide for the treatment of Parkinson's disease.
    Kandadai RM; Jabeen SA; Kanikannan MA; Borgohain R
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):747-59. PubMed ID: 25300164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in the pharmacological treatment of Parkinson's disease: targeting neurotransmitter systems.
    Brichta L; Greengard P; Flajolet M
    Trends Neurosci; 2013 Sep; 36(9):543-54. PubMed ID: 23876424
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Future Directions for Developing Non-dopaminergic Strategies for the Treatment of Parkinson's Disease.
    van Wamelen DJ; Leta V; Chaudhuri KR; Jenner P
    Curr Neuropharmacol; 2024; 22(10):1606-1620. PubMed ID: 37526188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.
    Parkinson Study Group
    JAMA; 2000 Oct; 284(15):1931-8. PubMed ID: 11035889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel pharmacological targets for the treatment of Parkinson's disease.
    Schapira AH; Bezard E; Brotchie J; Calon F; Collingridge GL; Ferger B; Hengerer B; Hirsch E; Jenner P; Le Novère N; Obeso JA; Schwarzschild MA; Spampinato U; Davidai G
    Nat Rev Drug Discov; 2006 Oct; 5(10):845-54. PubMed ID: 17016425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
    Jing XZ; Yuan XZ; Luo X; Zhang SY; Wang XP
    Curr Neuropharmacol; 2023; 21(8):1806-1826. PubMed ID: 35193486
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough.
    Lang AE; Obeso JA
    Lancet Neurol; 2004 May; 3(5):309-16. PubMed ID: 15099546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New treatments for the motor symptoms of Parkinson's disease.
    Vijverman AC; Fox SH
    Expert Rev Clin Pharmacol; 2014 Nov; 7(6):761-77. PubMed ID: 25318835
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Does levodopa slow or hasten the rate of progression of Parkinson's disease?
    Fahn S;
    J Neurol; 2005 Oct; 252 Suppl 4():IV37-IV42. PubMed ID: 16222436
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-Dopaminergic Treatments for Motor Control in Parkinson's Disease: An Update.
    Gonzalez-Latapi P; Bhowmick SS; Saranza G; Fox SH
    CNS Drugs; 2020 Oct; 34(10):1025-1044. PubMed ID: 32785890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newly Approved and Investigational Drugs for Motor Symptom Control in Parkinson's Disease.
    Di Luca DG; Reyes NGD; Fox SH
    Drugs; 2022 Jul; 82(10):1027-1053. PubMed ID: 35841520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of glutamatergic neurotransmission in the motor and non-motor symptoms in Parkinson's disease: Clinical cases and a review of the literature.
    Pagonabarraga J; Tinazzi M; Caccia C; Jost WH
    J Clin Neurosci; 2021 Aug; 90():178-183. PubMed ID: 34275546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent Advances in Drug Therapy for Parkinson's Disease.
    Murakami H; Shiraishi T; Umehara T; Omoto S; Iguchi Y
    Intern Med; 2023 Jan; 62(1):33-42. PubMed ID: 35110492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.